CLINICAL_TRIALS ClinicalTrials.gov record update

Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06383819
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:44.483443+00:00
Published At: 2025-06-03T00:00:00+00:00
Record Updated At: 2025-06-03
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Post-Acute COVID-19 Syndrome", "Lung Disease With Polymyositis", "Fibrosis", "Lung Diseases, Interstitial", "Lung; Disease, Interstitial, With Fibrosis"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-06-03"
protocolSection.identificationModule.nctId: "NCT06383819"
protocolSection.identificationModule.officialTitle: "Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Longidaza\u00ae for the Treatment of Patients With Residual Changes in the Lungs After COVID-19"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.